Table 3.
IRR and 95% CI for individual outcomes in pre-defined risk periods immediately before and after exposure to vaccination and before and after a positive SARS-CoV-2 test result, adjusted for calendar time from 1 December 2020 to 31 May 2021
| Time period | ChAdOx1nCoV-19 vaccine | BNT162b2 mRNA vaccine | Positive SARS-CoV-2 test | |||
|---|---|---|---|---|---|---|
| Events | IRR (95% CI) | Events | IRR (95% CI) | Events | IRR (95% CI) | |
| Acute CNS demyelinating events | ||||||
| Baseline | 473 | 1.00 | 244 | 1.00 | 53 | 1.00 |
| −28 to −1 days | 117 | 0.83 (0.67–1.03) | 58 | 0.92 (0.68–1.24) | 27 | 2.94 (1.79–4.83) |
| Day 0 | 0 | NA | * | 0.43 (0.16–3.05) | 7 | 19.34 (8.63–43.38) |
| 1–7 days | 38 | 1.03 (0.73–1.44) | 15 | 0.91 (0.53–1.55) | 9 | 3.45 (1.67–7.14) |
| 8–14 days | 35 | 0.95 (0.67–1.36) | 16 | 0.94 (0.56–1.58) | 7 | 2.61 (1.17–5.84) |
| 15–21 days | 38 | 1.04 (0.74–1.46) | 16 | 0.92 (0.55–1.55) | 6 | 2.05 (0.87–4.82) |
| 22–28 days | 33 | 0.93 (0.65–1.33) | 21 | 1.19 (0.75–1.89) | * | 0.60 (0.15–2.47) |
| 1–28 days | 144 | 0.97 (0.78–1.22) | 68 | 1.02 (0.75–1.40) | * | 1.67 (0.93–3.00) |
| Encephalitis, meningitis and myelitis | ||||||
| Baseline | 602 | 1.00 | 275 | 1.00 | 66 | 1.00 |
| −28 to −1 days | 78 | 0.42 (0.33–0.54) | 45 | 0.59 (0.42–0.82) | 78 | 5.64 (3.91–8.13) |
| Day 0 | * | 0.46 (0.15–1.43) | 0 | NA | 23 | 38.57 (23.41–63.56) |
| 1–7 days | 52 | 1.15 (0.85–1.54) | 22 | 1.02 (0.65–1.61) | 24 | 5.71 (3.49–9.32) |
| 8–14 days | 58 | 1.32 (0.99–1.76) | 27 | 1.17 (0.77–1.77) | 24 | 5.63 (3.46–9.15) |
| 15–21 days | 37 | 0.89 (0.63–1.25) | 21 | 0.95 (0.60–1.50) | 6 | 1.38 (0.59–3.21) |
| 22–28 days | 38 | 0.96 (0.68–1.35) | 27 | 1.28 (0.85–1.93) | 6 | 1.33 (0.57–3.08) |
| 1–28 days | 185 | 1.07 (0.87–1.31) | 97 | 1.14 (0.86–1.51) | 60 | 2.70 (1.78–4.11) |
| Guillain–Barré syndrome | ||||||
| Baseline | 264 | 1.00 | 109 | 1.00 | 30 | 1.00 |
| −28 to −1 days | 41 | 0.44 (0.31–0.63) | 21 | 0.67 (0.41–1.10) | 23 | 4.85 (2.67–8.82) |
| Day 0 | 0 | NA | 0 | NA | 7 | 33.37 (14.21–78.36) |
| 1–7 days | 17 | 0.74 (0.44–1.23) | 9 | 0.99 (0.49–2.00) | 11 | 7.36 (3.57–15.18) |
| 8–14 days | 23 | 1.02 (0.65–1.59) | 7 | 0.71 (0.32–1.56) | 8 | 5.19 (2.31–11.65) |
| 15–21 days | 65 | 2.90 (2.15–3.92) | 9 | 0.91 (0.45–1.84) | 11 | 6.89 (3.37–14.09) |
| 22–28 days | 48 | 2.21 (1.59–3.09) | 9 | 0.90 (0.45–1.82) | 6 | 3.51 (1.44–8.57) |
| 1–28 days | 153 | 2.04 (1.60–2.60) | 34 | 0.86 (0.54–1.36) | 36 | 5.25 (3.00–9.18) |
| Bell’s palsy | ||||||
| Baseline | 1,356 | 1.00 | 712 | 1.00 | 134 | 1.00 |
| −28 to −1 days | 328 | 0.80 (0.70–0.91) | 168 | 0.77 (0.65–0.92) | 86 | 3.34 (2.49–4.48) |
| Day 0 | 5 | 0.33 (0.14–0.80) | * | 0.36 (0.12–1.13) | 35 | 33.23 (22.57–48.94) |
| 1–7 days | 95 | 0.89 (0.72–1.11) | 54 | 0.91 (0.69–1.21) | 44 | 5.84 (4.09–8.33) |
| 8–14 days | 84 | 0.79 (0.63–0.99) | 57 | 0.95 (0.72–1.25) | 17 | 2.17 (1.30–3.63) |
| 15–21 days | 136 | 1.29 (1.08–1.56) | 65 | 1.05 (0.81–1.37) | 9 | 1.09 (0.55–2.15) |
| 22–28 days | 115 | 1.13 (0.92–1.37) | 71 | 1.17 (0.91–1.50) | 7 | 0.80 (0.37–1.72) |
| 1–28 days | 430 | 1.07 (0.94–1.21) | 247 | 1.06 (0.90–1.26) | 77 | 1.34 (0.91–1.97) |
| Myasthenic disorder | ||||||
| Baseline | 311 | 1.00 | 213 | 1.00 | 32 | 1.00 |
| −28 to −1 days | 70 | 0.72 (0.54–0.96) | 44 | 0.58 (0.41–0.83) | 26 | 4.00 (2.30–6.96) |
| Day 0 | 0 | NA | * | 0.96 (0.30–3.04) | 18 | 61.32 (33.43–112.50) |
| 1–7 days | 17 | 0.70 (0.42–1.16) | 18 | 0.83 (0.50–1.37) | 29 | 13.74 (8.07–23.41) |
| 8–14 days | 26 | 1.16 (0.76–1.77) | 24 | 1.09 (0.70–1.71) | 9 | 3.98 (1.86–8.52) |
| 15–21 days | 33 | 1.57 (1.07–2.30) | 22 | 1.02 (0.64–1.63) | 5 | 2.17 (0.84–5.63) |
| 22–28 days | 23 | 1.01 (0.65–1.57) | 27 | 1.46 (0.96–2.22) | 6 | 2.81 (1.16–6.79) |
| 1–28 days | 99 | 1.23 (0.94–1.62) | 91 | 1.18 (0.88–1.59) | 49 | 3.01 (1.70–5.36) |
| Hemorrhagic stroke | ||||||
| Baseline | 1,456 | 1.00 | 811 | 1.00 | 173 | 1.00 |
| −28 to −1 days | 232 | 0.47 (0.41–0.55) | 86 | 0.36 (0.29–0.46) | 163 | 4.73 (3.72–6.02) |
| Day 0 | 7 | 0.37 (0.18–0.78) | 6 | 0.59 (0.27–1.33) | 20 | 12.42 (7.73–19.95) |
| 1–7 days | 131 | 0.98 (0.82–1.18) | 93 | 1.27 (1.02–1.59) | 23 | 2.01 (1.29–3.15) |
| 8–14 days | 141 | 1.06 (0.89–1.27) | 89 | 1.18 (0.94–1.48) | 14 | 1.19 (0.69–2.07) |
| 15–21 days | 128 | 0.98 (0.81–1.18) | 106 | 1.38 (1.12–1.71) | 10 | 0.84 (0.44–1.61) |
| 22–28 days | 126 | 1.00 (0.83–1.21) | 91 | 1.15 (0.92–1.44) | 6 | 0.51 (0.23–1.16) |
| 1–28 days | 526 | 1.02 (0.90–1.15) | 379 | 1.24 (1.07–1.43) | 53 | 0.85 (0.57–1.26) |
| Subarachnoid hemorrhage | ||||||
| Baseline | 971 | 1.00 | 415 | 1.00 | 88 | 1.00 |
| −28 to −1 days | 157 | 0.49 (0.41–0.58) | 53 | 0.43 (0.32–0.58) | 60 | 3.40 (2.38–4.86) |
| Day 0 | * | 0.34 (0.13–0.91) | 0 | NA | 19 | 24.22 (14.50–40.45) |
| 1–7 days | 70 | 0.85 (0.66–1.10) | 38 | 1.08 (0.77–1.52) | 23 | 4.17 (2.59–6.71) |
| 8–14 days | 93 | 1.16 (0.93–1.44) | 41 | 1.14 (0.82–1.59) | 12 | 2.15 (1.16–3.99) |
| 15–21 days | 72 | 0.92 (0.72–1.18) | 31 | 0.85 (0.58–1.23) | 7 | 1.23 (0.57–2.67) |
| 22–28 days | 69 | 0.94 (0.73–1.20) | 41 | 1.16 (0.84–1.61) | 7 | 1.19 (0.55–2.58) |
| 1–28 days | 304 | 1.01 (0.86–1.18) | 151 | 1.05 (0.84–1.30) | 49 | 1.51 (0.96–2.36) |
*Cells with <5 are suppressed.
NA, not applicable.